SCHEMBL6826773

SCHEMBL6826773

Cc1ccc(C(=O)CSc2ccc(F)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.60
MEN1 O00255 3/20 0.60
POLB P06746 3/20 0.58
ATM Q13315 1/20 0.57
HSD11B1 P28845 1/20 0.55
ALDH1A1 P00352 4/20 0.54
HPGD P15428 3/20 0.54
KDM4E B2RXH2 2/20 0.54
PKM P14618 1/20 0.54
ALOX12 P18054 1/20 0.54
MAPK1 P28482 1/20 0.54
NPC1 O15118 7/20 0.52
RAB9A P51151 6/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 1/20 0.52
RECQL P46063 1/20 0.52
EPHX2 P34913 1/20 0.51
HSD17B10 Q99714 2/20 0.50
LMNA P02545 1/20 0.50
PAX8 Q06710 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9786927 0.85 MEN1 (0.67) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL6826443 0.83 KMT2A (0.63) KMT2AMEN1POLBHSD11B1ALDH1A1
SCHEMBL9787103 0.83 KMT2A (0.63) KMT2AMEN1POLBHSD11B1ALDH1A1
SCHEMBL28504230 0.83 CA1 (0.62) KMT2AMEN1POLBHSD11B1ALDH1A1
SCHEMBL9565777 0.83 MEN1 (0.64) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL11811575 0.83 RAB9A (0.65) KMT2AMEN1POLBALDH1A1HPGD
SCHEMBL9775143 0.81 ALDH1A1 (0.58) KMT2AMEN1POLBATMALDH1A1
SCHEMBL17154293 0.81 HSD11B1 (0.50) KMT2AMEN1POLBHSD11B1ALDH1A1
SCHEMBL28497894 0.81 NPC1 (0.63) KMT2AMEN1POLBHSD11B1ALDH1A1
SCHEMBL13182758 0.80 KMT2A (0.60) KMT2AMEN1POLBALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R KMT2A 3944/4885MEN1 3139/4885POLB 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.